(NASDAQ: NVAX) Novavax's forecast annual revenue growth rate of -38.83% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Novavax's revenue in 2025 is $1,254,962,000.On average, 5 Wall Street analysts forecast NVAX's revenue for 2025 to be $152,628,860,726, with the lowest NVAX revenue forecast at $70,327,520,760, and the highest NVAX revenue forecast at $204,293,187,319. On average, 4 Wall Street analysts forecast NVAX's revenue for 2026 to be $83,649,905,001, with the lowest NVAX revenue forecast at $52,520,501,800, and the highest NVAX revenue forecast at $161,403,441,817.
In 2027, NVAX is forecast to generate $53,153,319,910 in revenue, with the lowest revenue forecast at $43,845,370,497 and the highest revenue forecast at $64,279,548,339.